$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000143922220000069 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$44.05M	$34.71M	$26.02M
YoY Change	24.28%	33.36%	71.23%
Cost Of Revenue	$960.0K	$638.0K	$393.0K
YoY Change	231.03%	62.34%	-43.45%
Gross Profit	$43.09M	$34.07M	$25.63M
YoY Change	22.59%	32.92%	76.73%
Gross Profit Margin	97.83%	98.16%	98.49%
Selling, General & Admin	$39.78M	$34.84M	$33.02M
YoY Change	14.21%	5.51%	6.17%
% of Gross Profit	92.32%	102.27%	128.83%
Research & Development	$95.74M	$51.94M	$101.7M
YoY Change	-9.89%	-48.91%	23.15%
% of Gross Profit	222.19%	152.47%	396.68%
Depreciation & Amortization	$2.700M	$2.400M	$2.100M
YoY Change	35.0%	14.29%	16.67%
% of Gross Profit	6.27%	7.04%	8.19%
Operating Expenses	$135.5M	$51.94M	$135.1M
YoY Change	-3.94%	-61.55%	18.12%
Operating Profit	-$92.43M	-$80.29M	-$109.1M
YoY Change	-12.74%	-26.38%	9.98%
Interest Expense	$790.0K	$1.120M	$2.890M
YoY Change	-77.93%	-61.25%	-35.78%
% of Operating Profit
Other Income/Expense, Net	-$6.010M	$0.00
YoY Change
Pretax Income	-$84.54M	-$79.18M	-$106.2M
YoY Change	-17.4%	-25.43%	12.16%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$97.66M	-$98.98M	-$106.2M
YoY Change	-4.58%	-6.78%	12.16%
Net Earnings / Revenue	-221.73%	-285.19%	-407.98%
Basic Earnings Per Share	-$1.41	-$1.43
Diluted Earnings Per Share	-$1.41	-$1.43	-$1.806M
COMMON SHARES
Basic Shares Outstanding	69.26M shares	69.14M shares	58.75M shares
Diluted Shares Outstanding		69.14M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$572.9M	$605.5M	$451.9M
YoY Change	1.43%	34.0%	-32.54%
Cash & Equivalents	$127.4M	$104.9M	$81.71M
Short-Term Investments	$445.5M	$500.7M	$370.2M
Other Short-Term Assets	$23.70M	$28.90M	$20.00M
YoY Change	-2.07%	44.5%	21.21%
Inventory	$14.70M	$11.37M	$5.849M
Prepaid Expenses
Receivables	$21.30M	$19.00M	$9.700M
Other Receivables	$0.00	$4.300M	$2.700M
Total Short-Term Assets	$636.7M	$669.1M	$490.1M
YoY Change	4.08%	36.51%	-29.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.82M	$33.50M	$24.06M
YoY Change	-2.09%	39.21%	-2.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$97.60M	$116.9M	$88.60M
YoY Change	-36.17%	31.94%	-57.51%
Other Assets	$0.00	$1.350M	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$216.3M	$239.4M	$208.5M
YoY Change	-22.49%	14.82%	-10.73%
TOTAL ASSETS
Total Short-Term Assets	$636.7M	$669.1M	$490.1M
Total Long-Term Assets	$216.3M	$239.4M	$208.5M
Total Assets	$853.0M	$908.4M	$698.6M
YoY Change	-4.24%	30.04%	-24.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.72M	$12.85M	$21.51M
YoY Change	-19.05%	-40.25%	29.46%
Accrued Expenses	$30.80M	$49.72M	$46.75M
YoY Change	-42.04%	6.36%	84.76%
Deferred Revenue	$0.00	$0.00	$16.87M
YoY Change	-100.0%	-100.0%	-59.96%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$300.0K	$300.0K
YoY Change	0.0%
Total Short-Term Liabilities	$94.39M	$69.77M	$92.43M
YoY Change	1.62%	-24.52%	9.07%
LONG-TERM LIABILITIES
Long-Term Debt	$300.0K	$400.0K	$0.00
YoY Change	-57.14%
Other Long-Term Liabilities	$358.7M	$357.8M	$157.9M
YoY Change	128.91%	126.6%	87.75%
Total Long-Term Liabilities	$359.0M	$358.2M	$157.9M
YoY Change	128.08%	126.85%	87.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.39M	$69.77M	$92.43M
Total Long-Term Liabilities	$359.0M	$358.2M	$157.9M
Total Liabilities	$453.5M	$428.0M	$250.3M
YoY Change	81.23%	70.98%	48.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.843B	-$1.746B	-$1.414B
YoY Change	21.59%	23.49%	39.58%
Common Stock	$2.243B	$2.226B	$1.862B
YoY Change	4.01%	19.55%	4.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$399.5M	$480.5M	$448.3M
YoY Change
Total Liabilities & Shareholders Equity	$853.0M	$908.4M	$698.6M
YoY Change	-4.24%	30.04%	-24.81%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$97.66M	-$98.98M	-$106.2M
YoY Change	-4.58%	-6.78%	12.16%
Depreciation, Depletion And Amortization	$2.700M	$2.400M	$2.100M
YoY Change	35.0%	14.29%	16.67%
Cash From Operating Activities	-$49.40M	-$68.20M	-$85.60M
YoY Change	-47.22%	-20.33%	34.17%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$5.200M	-$2.000M
YoY Change	-85.51%	160.0%	-35.48%
Acquisitions
YoY Change
Other Investing Activities	$72.50M	-$121.1M	$82.50M
YoY Change	-140.73%	-246.79%	1298.31%
Cash From Investing Activities	$71.30M	-$126.2M	$80.40M
YoY Change	-138.58%	-256.97%	2771.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	3.400M	3.300M
YoY Change	-99.78%	3.03%	-54.17%
NET CHANGE
Cash From Operating Activities	-49.40M	-68.20M	-85.60M
Cash From Investing Activities	71.30M	-126.2M	80.40M
Cash From Financing Activities	600.0K	3.400M	3.300M
Net Change In Cash	22.50M	-191.0M	-1.900M
YoY Change	-2912.5%	9952.63%	-96.47%
FREE CASH FLOW
Cash From Operating Activities	-$49.40M	-$68.20M	-$85.60M
Capital Expenditures	-$1.000M	-$5.200M	-$2.000M
Free Cash Flow	-$48.40M	-$63.00M	-$83.60M
YoY Change	-44.18%	-24.64%	37.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36014
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0662915
	dei	Entity Address Address Line1 EntityAddressAddressLine1	88 Sidney Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	649-8600
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 per share
	dei	Trading Symbol TradingSymbol	AGIO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69259817	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104855000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80931000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	500684000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	483946000	USD
CY2020Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	18989000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8952000	USD
CY2020Q3	agio	Collaboration Receivable Due From Related Parties Current CollaborationReceivableDueFromRelatedPartiesCurrent	2334000	USD
CY2019Q4	agio	Collaboration Receivable Due From Related Parties Current CollaborationReceivableDueFromRelatedPartiesCurrent	1539000	USD
CY2020Q3	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	1992000	USD
CY2019Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	1928000	USD
CY2020Q3	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2019Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	2900000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	11371000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	7331000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28861000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24177000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	669086000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	611704000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	116889000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	152929000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86952000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93643000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33495000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31472000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	677000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	993000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1350000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q3	us-gaap	Assets Assets	908449000	USD
CY2019Q4	us-gaap	Assets Assets	890741000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12853000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21896000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49724000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53142000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10933000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6881000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6642000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	313000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	273000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	69771000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92886000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	50580000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	99693000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	106074000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	412000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	673000	USD
CY2020Q3	agio	Sale Of Future Revenue Liability Noncurrent SaleOfFutureRevenueLiabilityNoncurrent	258121000	USD
CY2019Q4	agio	Sale Of Future Revenue Liability Noncurrent SaleOfFutureRevenueLiabilityNoncurrent	0	USD
CY2020Q3	us-gaap	Liabilities Liabilities	427997000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	250213000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69198063	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69198063	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68401105	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68401105	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	69000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2225538000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	10900000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2156363000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	663000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	202000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1745818000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1516105000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	480452000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640528000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	908449000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	890741000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34706000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26024000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	159151000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82472000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	638000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	393000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1846000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1030000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89555000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101672000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	271728000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	304646000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34840000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33019000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	109292000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	97200000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	125033000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	135084000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	382866000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	402876000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-90327000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-109060000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-223715000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-320404000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1115000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2887000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5820000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11282000	USD
CY2020Q3	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	9767000	USD
CY2019Q3	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	11818000	USD
	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-106173000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-309122000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.27
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69144061	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58803534	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68905853	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58661607	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-106173000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-309122000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-973000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-26000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	461000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2635000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99952000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106199000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-229252000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-306487000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640528000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5465000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19690000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-128000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-40256000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	625299000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1652000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20430000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1562000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-90478000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	558465000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3532000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18407000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-973000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-98979000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	480452000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	687537000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6003000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18108000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1687000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-93078000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	620257000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2770000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18547000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	974000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-109871000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	532677000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3225000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18588000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-106173000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	448291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-229713000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-309122000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7307000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6124000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	58527000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	55243000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1521000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2772000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-466000	USD
	agio	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	6691000	USD
	agio	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	6341000	USD
	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	11818000	USD
	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
	agio	Royalty Revenue Non Cash RoyaltyRevenueNonCash	4341000	USD
	agio	Royalty Revenue Non Cash RoyaltyRevenueNonCash	0	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	10037000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2030000	USD
	agio	Increase Decrease In Collaboration Receivable Due From Related Parties Current IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent	795000	USD
	agio	Increase Decrease In Collaboration Receivable Due From Related Parties Current IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent	-624000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23924000	USD
	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	64000	USD
	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	199000	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	-2900000	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	366000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4040000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4980000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6033000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3552000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7640000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2649000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	162000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4602000	USD
	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-61513000	USD
	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-25849000	USD
	agio	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6112000	USD
	agio	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4190000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-241362000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11207000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80931000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-277011000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	430624000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	194822000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	448866000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	476382000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13892000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5347000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4350000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	276213000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	250000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10649000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12005000	USD
	agio	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	250537000	USD
	agio	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	260936000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12005000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70502000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104855000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81709000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	185000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2089000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	3500000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	42322000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2020Q2	agio	Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold	255000000.0	USD
CY2020Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	722400000	USD
CY2019Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	616910000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	834000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	171000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	617573000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	636673000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	470000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	268000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	636875000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	74	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	113	security
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	247700000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	345700000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1406000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	180000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9166000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6808000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	799000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	343000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	11371000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	7331000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P7Y
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3800000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	11400000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3800000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	10600000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2200000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	8500000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2364000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14380000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16773000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18126000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	18660000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	19507000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	44385000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	134195000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	27621000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	106574000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19044000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18982000	USD
CY2020Q3	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	16188000	USD
CY2019Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	21777000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3474000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8335000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11018000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4048000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49724000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53142000	USD
CY2019Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	874000	USD
CY2019Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	1124000	USD
CY2019Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	1798000	USD
CY2019Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	3796000	USD
	agio	Current Year Provision For Contractual Adjustments CurrentYearProvisionForContractualAdjustments	10261000	USD
	agio	Current Year Provisions For Rebate Reserve CurrentYearProvisionsForRebateReserve	9299000	USD
	agio	Provision For Right To Recover Product In Current Year ProvisionForRightToRecoverProductInCurrentYear	1296000	USD
	agio	Contract With Customer Current Year Reserve Provisions ContractWithCustomerCurrentYearReserveProvisions	20856000	USD
	agio	Prior Year Provision For Contractual Adjustments PriorYearProvisionForContractualAdjustments	-3000	USD
	agio	Prior Year Provisions For Rebate Reserve PriorYearProvisionsForRebateReserve	122000	USD
	agio	Provision For Right To Recover Product In Prior Years ProvisionForRightToRecoverProductInPriorYears	-476000	USD
	agio	Contract With Customer Prior Years Reserve Provisions ContractWithCustomerPriorYearsReserveProvisions	-357000	USD
	agio	Contract With Customer Contract Adjustment Recoveries Current Year ContractWithCustomerContractAdjustmentRecoveriesCurrentYear	8966000	USD
	agio	Contract With Customer Rebate Reserve Recoveries In Current Year ContractWithCustomerRebateReserveRecoveriesInCurrentYear	2260000	USD
	agio	Contract With Customer Right To Recover Product Current Year Recoveries ContractWithCustomerRightToRecoverProductCurrentYearRecoveries	0	USD
	agio	Contract With Customer Current Year Reserve Recoveries ContractWithCustomerCurrentYearReserveRecoveries	11226000	USD
	agio	Contract With Customer Contract Adjustment Recoveries Prior Year ContractWithCustomerContractAdjustmentRecoveriesPriorYear	653000	USD
	agio	Contract With Customer Rebate Reserve Recoveries In Prior Years ContractWithCustomerRebateReserveRecoveriesInPriorYears	677000	USD
	agio	Contract With Customer Right To Recover Product Prior Year Recoveries ContractWithCustomerRightToRecoverProductPriorYearRecoveries	0	USD
	agio	Contract With Customer Prior Years Reserve Recoveries ContractWithCustomerPriorYearsReserveRecoveries	1330000	USD
CY2020Q3	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	1513000	USD
CY2020Q3	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	7608000	USD
CY2020Q3	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	2618000	USD
CY2020Q3	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	11739000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	732000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	540000	USD
CY2020Q3	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	11007000	USD
CY2019Q4	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	3256000	USD
CY2020Q3	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	11739000	USD
CY2019Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	3796000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	8952000	USD
	agio	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	102504000	USD
	agio	Contract With Customer Asset Proceeds From Collection Of Receivables ContractWithCustomerAssetProceedsFromCollectionOfReceivables	92467000	USD
CY2020Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	18989000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4404000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	61513000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	28823000	USD
CY2020Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2019Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4500000	USD
	agio	Revenue From Contracts With Customers Milestone Revenue Recognized RevenueFromContractsWithCustomersMilestoneRevenueRecognized	0	USD
	agio	Revenue From Contracts With Customers Milestone Revenue Recognized RevenueFromContractsWithCustomersMilestoneRevenueRecognized	0	USD
CY2019Q3	agio	Revenue From Contracts With Customers Milestone Revenue Recognized RevenueFromContractsWithCustomersMilestoneRevenueRecognized	0	USD
CY2020Q3	agio	Revenue From Contracts With Customers Milestone Revenue Recognized RevenueFromContractsWithCustomersMilestoneRevenueRecognized	0	USD
CY2020Q2	agio	Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Estimated Effective Interest Rate PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate	0.164
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6201485	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	956945	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	49.84
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	339284	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	19.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	448901	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	65.98
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6370245	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.85
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4067553	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	61.23
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6370245	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	58.85
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18407000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18588000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58527000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55243000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18407000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18588000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58527000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55243000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7588924	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7588924	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6932789	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6932789	shares

Files In Submission

Name	View Source	Status
0001439222-20-000069-index-headers.html	Edgar Link	pending
0001439222-20-000069-index.html	Edgar Link	pending
0001439222-20-000069.txt	Edgar Link	pending
0001439222-20-000069-xbrl.zip	Edgar Link	pending
agio-20200930.htm	Edgar Link	pending
agio-20200930.xsd	Edgar Link	pending
agio-20200930_cal.xml	Edgar Link	unprocessable
agio-20200930_def.xml	Edgar Link	unprocessable
agio-20200930_htm.xml	Edgar Link	completed
agio-20200930_lab.xml	Edgar Link	unprocessable
agio-20200930_pre.xml	Edgar Link	unprocessable
exhibit31-1x09x30x20.htm	Edgar Link	pending
exhibit31-2x09x30x20.htm	Edgar Link	pending
exhibit32-1x09x30x20.htm	Edgar Link	pending
exhibit32-2x09x30x20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2020 Q4 Form 10-Q Financial Statement

#000143922220000069 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2020 Q4 Form 10-Q Financial Statement

#000143922220000069 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio